VI
NBIX icon

Vestcor Inc’s Neurocrine Biosciences NBIX Stock Holding History

Vestcor Inc’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Buy
10,439
+2,800
+37% +$415K 0.04% 380
2026
Q1 		$1.01M Sell
7,639
-16,785
-69% -$2.23M 0.03% 496
2025
Q4 		$3.46M Buy
24,424
+1,680
+7% +$243K 0.1% 215
2025
Q3 		$3.19M Buy
22,744
+1,230
+6% +$167K 0.1% 227
2025
Q2 		$2.7M Buy
21,514
+83
+0.4% +$9.52K 0.08% 270
2025
Q1 		$2.37M Buy
21,431
+1,565
+8% +$198K 0.08% 262
2024
Q4 		$2.71M Sell
19,866
-342
-2% -$42.3K 0.09% 232
2024
Q3 		$2.33M Sell
20,208
-4,884
-19% -$670K 0.07% 261
2024
Q2 		$3.45M Hold
25,092
– – 0.12% 195
2024
Q1 		$3.46M Sell
25,092
-258
-1% -$35.2K 0.12% 193
2023
Q4 		$3.34M Buy
25,350
+981
+4% +$113K 0.11% 188
2023
Q3 		$2.74M Buy
24,369
+7,128
+41% +$751K 0.1% 206
2023
Q2 		$1.63M Buy
17,241
+3,799
+28% +$371K 0.06% 319
2023
Q1 		$1.36M Hold
13,442
– – 0.05% 368
2022
Q4 		$1.61M Buy
13,442
+6,426
+92% +$753K 0.06% 348
2022
Q3 		$745K Buy
7,016
+4,800
+217% +$487K 0.03% 563
2022
Q2 		$216K Buy
2,216
+716
+48% +$66.1K 0.01% 893
2022
Q1 		$141K Sell
1,500
-1,896
-56% -$161K ﹤0.01% 1018
2021
Q4 		$289K Sell
3,396
-482
-12% -$44.3K 0.01% 761
2021
Q3 		$372K Sell
3,878
-178
-4% -$16.8K 0.01% 667
2021
Q2 		$395K Buy
4,056
+1,577
+64% +$151K 0.01% 681
2021
Q1 		$241K Hold
2,479
– – 0.01% 777
2020
Q4 		$238K Hold
2,479
– – 0.01% 704
2020
Q3 		$238K Hold
2,479
– – 0.01% 629
2020
Q2 		$302K Buy
+2,479
New +$274K 0.02% 515

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vestcor Inc's NBIX Position: Q2 2026 in Review

Vestcor Inc increased its Neurocrine Biosciences (NBIX) stake by 37% in Q2 2026, buying an estimated $415K and bringing the position to 10,439 shares worth $1.76M. The position accounts for 0.04% of the portfolio, ranked #380.

Vestcor Inc first reported a position in NBIX in Q2 2020 and has held it in 25 quarters since. The position peaked at $3.46M in Q4 2025. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Vestcor Inc held 10,439 shares of Neurocrine Biosciences worth $1.76M as of Q2 2026.
  • Vestcor Inc bought 2,800 Neurocrine Biosciences shares in Q2 2026, an estimated $415K.
  • Neurocrine Biosciences made up 0.04% of Vestcor Inc's portfolio in Q2 2026, its #380 holding.
  • Vestcor Inc first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 25 quarters since.
  • Vestcor Inc's Neurocrine Biosciences position peaked at $3.46M in Q4 2025.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Vestcor Inc's 13F filing for Q2 2026, filed 11 Aug 2026.